المؤلفون: Daphne Day, Lillian L. Siu

المصدر: Genome Medicine, Vol 8, Iss 1, Pp 1-14 (2016)

مصطلحات موضوعية: Maximum Tolerate Dose, Ipilimumab, Crizotinib, Clinical Trial Design, Precision Medicine, Medicine, Genetics, QH426-470

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s13073-016-0369-xTest; https://doaj.org/toc/1756-994XTest

الوصول الحر: https://doaj.org/article/457f80e2b950432ab3fbd73ededb7e61Test

المؤلفون: Kabirraaj Toor, Srividya Kotapati, Mark R. Middleton, Adenike Amadi, Andriy Moshyk, Keith Chan

المصدر: BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Efficacy, Pyridones, Ipilimumab, Pyrimidinones, Pembrolizumab, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, Disease-Free Survival, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Genetics, medicine, Adjuvant therapy, Humans, 030212 general & internal medicine, Network meta-analysis, Melanoma, Trametinib, business.industry, Hazard ratio, Systematic literature review, Imidazoles, Bayes Theorem, Dabrafenib, Adjuvant treatment, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Nivolumab, 030220 oncology & carcinogenesis, Patient Safety, Safety, business, Research Article, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc98a3a5f691ad489a874fb3c12695abTest
https://doaj.org/article/9229b82e8dee4f2dbaac9757d91d7c68Test

المؤلفون: van Bussel, Mark T J, Beijnen, Jos H, Brandsma, Dieta, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

المساهمون: Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

المصدر: BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer
BMC Cancer, 19(1). BioMed Central

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, melanoma brain mestases, Neonatal fc receptor, Phases of clinical research, Ipilimumab, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Cerebrospinal fluid, Antineoplastic Agents, Immunological, Clinical Trials, Phase II as Topic, Pharmacokinetics, Surgical oncology, Internal medicine, Genetics, pharmacodynamics, Medicine, Humans, ipilimumab, Melanoma, nivolumab, business.industry, Brain Neoplasms, neonatal fc receptor, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Melanoma brain metastases, 030104 developmental biology, Nivolumab, Clinical Trials, Phase III as Topic, Pharmacodynamics, 030220 oncology & carcinogenesis, business, pharmacokinetics, medicine.drug, Research Article

وصف الملف: image/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c743679228d29e2669d46c2feaccf653Test
http://link.springer.com/article/10.1186/s12885-019-5741-yTest

المؤلفون: Sven Nilsson, Salah-Eddin Al-Batran, Albrecht Kretzschmar, Thomas J. Ettrich, Daniel Pink, Susanna Hegewisch-Becker, Jorge Riera Knorrenschild, Eray Goekkurt, Peter C. Thuss-Patience, Mascha Binder, U. Lindig, Axel Hinke, Joseph Tintelnot, Sylvie Lorenzen, Lutz Jacobasch, Alexander Stein, Carsten Bokemeyer

المصدر: BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Esophageal Neoplasms, Organoplatinum Compounds, Receptor, ErbB-2, Leucovorin, Pembrolizumab, Study Protocol, 0302 clinical medicine, Antineoplastic Agents, Immunological, FOLFOX, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Multicenter Studies as Topic, Immune Checkpoint Inhibitors, Randomized Controlled Trials as Topic, Esophagogastric adenocarcinoma, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Progression-Free Survival, Nivolumab, Docetaxel, 030220 oncology & carcinogenesis, Female, Esophagogastric Junction, Fluorouracil, Immunotherapy, medicine.drug, Adult, medicine.medical_specialty, Ipilimumab, Adenocarcinoma, lcsh:RC254-282, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Stomach Neoplasms, Internal medicine, HER2, Genetics, medicine, Humans, business.industry, Oxaliplatin, Regimen, 030104 developmental biology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c916e418de358ed25e3f40e3b1422c88Test
http://link.springer.com/article/10.1186/s12885-020-06958-3Test

المؤلفون: Michal Lotem, T. Kim Le, Jane Brokaw, Srividya Kotapati, Ana Arance, Brian Buysse, Jennifer Lord-Bessen, Frank Meiss, Laurent Mortier, Andriy Moshyk, Pippa Corrie, Stéphane Dalle, Ruth E Board, Susan D. Mathias, Kelly Oh, Ralf Gutzmer, Mark R. Middleton, Julie Scotto, Patrick Terheyden

المساهمون: Apollo - University of Cambridge Repository, Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Cambridge University Hospitals NHS Foundation Trust, Cambridge University Hospitals - NHS (CUH), University of Cambridge [UK] (CAM), Hadassah Hebrew University Hospital, The Hebrew University of Jerusalem (HUJ), Hadassah Hebrew University Medical Center [Jerusalem], Royal Preston Hospital [Preston, UK] (RPH), Hospital Clinic [Barcelona, Spain], University of Freiburg [Freiburg], Universität zu Lübeck = University of Lübeck [Lübeck], Medizinische Hochschule Hannover (MHH), Syneos Health [Morrisville, NC, USA] (SH), Bristol-Myers Squibb [Princeton], Health Outcomes Solutions [Winter Park, FL, USA] (HOS), Churchill Hospital [Breast Care Unit], Churchill Hospital Oxford Centre for Haematology, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Universität zu Lübeck [Lübeck], Malbec, Odile

المصدر: BMC Cancer
BMC Cancer, 2021, 21 (1), pp.642. ⟨10.1186/s12885-021-08032-y⟩
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer, BioMed Central, 2021, 21 (1), pp.642. ⟨10.1186/s12885-021-08032-y⟩

مصطلحات موضوعية: Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Systemic therapy, 0302 clinical medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Medicine, Overall survival, 030212 general & internal medicine, Prospective Studies, Immune Checkpoint Inhibitors, Melanoma, RC254-282, Aged, 80 and over, education.field_of_study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Chemoradiotherapy, Middle Aged, Advanced melanoma, 3. Good health, [SDV] Life Sciences [q-bio], Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Cohort, Female, medicine.drug, Research Article, Subsequent therapy, Quality of life, Adult, medicine.medical_specialty, Population, Ipilimumab, Radiosurgery, 03 medical and health sciences, Young Adult, Internal medicine, Genetics, Humans, Adverse effect, education, Aged, Chemotherapy, business.industry, Survival Analysis, Clinical trial, Radiation therapy, Real-world, business, Follow-Up Studies

وصف الملف: text/xml; application/pdf; application/zip

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a988ada341bbad946d43ff13cb331d97Test
https://ora.ox.ac.uk/objects/uuid:54880193-729d-489f-bed6-fb98def61d02Test

المؤلفون: Valesca P. Retèl, Melanie Lindenberg, Joost H. van den Berg, Wim H. van Harten, John B. A. G. Haanen, Maartje W. Rohaan

المساهمون: Health Technology & Services Research

المصدر: BMC cancer, 20(1):712. BioMed Central
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-14 (2020)

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Time Factors, Delphi Technique, Cost effectiveness, Cost-Benefit Analysis, Delphi method, Ipilimumab, Expert views, lcsh:RC254-282, Immunotherapy, Adoptive, Commercialization, Tumor-infiltrating lymphocytes, law.invention, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, Technology Transfer, 0302 clinical medicine, Randomized controlled trial, law, Genetics, medicine, Humans, Production (economics), Health technology assessment, Infusions, Intravenous, Immune Checkpoint Inhibitors, Melanoma, Randomized Controlled Trials as Topic, Advanced melanoma, Actuarial science, Uncertainty, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, Oncology, Anticipation (artificial intelligence), Health Care Surveys, Implementation, 030220 oncology & carcinogenesis, Business, Research Article, Forecasting, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77a873c17de92ebb5c99451bdc795df2Test
https://hdl.handle.net/1887/3627233Test

المؤلفون: Marin A McDonald, Julie Bykowski, Gregory A. Daniels, Parag Sanghvi

المصدر: BMC Cancer, Vol 18, Iss 1, Pp 1-5 (2018)
BMC Cancer

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Systemic disease, Skin Neoplasms, medicine.medical_treatment, Ipilimumab, Context (language use), Case Report, Metastatic melanoma, Intracranial metastases, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Checkpoint blockade, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Genetics, Medicine, Humans, Adverse effect, Melanoma, business.industry, Brain Neoplasms, Brain, Immunotherapy, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Magnetic Resonance Imaging, Immune checkpoint, Blockade, 030104 developmental biology, Nivolumab, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd4ccd92e7a715b1192aac41ed313964Test
http://link.springer.com/article/10.1186/s12885-018-4470-yTest